Ginkgo Bioworks (NYSE: DNA)
Ginkgo Bioworks Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ginkgo Bioworks Company Info
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
News & Analysis
Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today
The company is forging ahead with next-generation drug development solutions.
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Could this beaten-down stock turn things around in the near future?
This 1 AI Stock Could Revolutionize Biotech and Pharma
The company is using artificial intelligence, and planning to help others use AI empowered by its data collection.
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
The risks may resolve in a year or so but seizing the opportunities will take longer.
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
Its ambitious business model may not be sustainable.
Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?
Have shares of the troubled life sciences business fallen too far?
Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?
A recovery plan is underway, but it isn't a slam dunk.
Why Ginkgo Bioworks Stock Is Sinking Today
There was double trouble for this beaten-down biotech stock.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.